top of page
  • Writer's pictureOMNI Medical

Cannabis Stocks Soar: HHS Urges DEA to Reclassify Cannabis as Class III

Department of Health and Human Services (HHS) urges DEA to categorize marijuana as a lower-risk substance.


Historical Highlights:


  • Department of Health and Human Services (HHS) urges DEA to categorize marijuana as a lower-risk substance.

  • Stocks including Aurora Cannabis, Tilray Brands, Cronos Group, and SNDL Inc. see a significant rise.

  • Marijuana currently considered alongside drugs like heroin and LSD. The reclassification could pave the way for wider legalization.


A Glimmer of Hope for the Cannabis Industry


On Wednesday, the cannabis industry witnessed a significant boost as stocks including Aurora Cannabis, Tilray Brands, Cronos Group, and SNDL Inc. surged.


This followed the recommendation by the Department of Health and Human Services (HHS) for the Drug Enforcement Administration (DEA) to reconsider marijuana's classification, placing it as a lower-risk drug.

Department of Health and Human Services (HHS) urges DEA to categorize marijuana as a lower-risk substance.

Reclassification Recommendations Explained:


Currently, marijuana falls under the Schedule I category as per the Controlled Substances Act. This equates its potential for abuse to drugs like heroin and LSD. HHS's recommendation is based on a recent review by the Food and Drug Administration.


The proposed reclassification would:


  • Recognize marijuana’s moderate to low potential for dependence.

  • Accept its reduced potential for abuse.

  • Place it alongside substances like ketamine and testosterone.


Wider Implications:


While nearly 40 states in the U.S. have legalized marijuana in some capacity, it remains illicit in certain states and at the federal level. The proposed downgrade would not only reflect a more accurate risk associated with cannabis use but could also be a stepping stone towards more extensive legalization.


Administration's Stand on Cannabis


An HHS spokesperson commented on the swift response to President Biden’s directive, stating, "This administrative process was completed in less than 11 months..." This comes after President Biden’s request in October 2022 for a review of marijuana’s classification under federal law.


The Global Perspective:


Should the U.S. adjust marijuana's classification federally, it could open the doors for significant stock exchanges to list more cannabis businesses and welcome foreign cannabis products. It's noteworthy that cannabis is already legal in Canada, North America’s hub for publicly traded cannabis enterprises. These companies could potentially broaden their horizons to the U.S., following federal legalization.


Looking Ahead:


The move to reclassify marijuana showcases the administration's commitment to making informed decisions based on scientific data. This could signal a brighter future for the cannabis industry and the broader acceptance of its benefits.


Join OMNI Medical Cannabis Doctors Research Group Today


As we forge ahead in our relentless pursuit of better health outcomes, this study serves as a timely reminder: nature might just have the solutions we've been seeking all along. With continued research and an open mind, a brighter, less opioid-dependent future could be on the horizon.


Join OMNI Medical Cannabis Doctors Research Group Today


Want to join in Medical Cannabis Research?


Now you can with OMNI Medical Cannabis Research Group. Join today!


122 views

Comentarios


bottom of page